Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1914-1926

  Sleebs, Brad E ^a,b   Czabotar, Peter E ^a,b   Fairbrother, Wayne J ^c   Fairlie, W Douglas ^a,b   Flygare, John A ^c   Huang, David C S ^a,b   Kersten, Wilhelmus J A ^a,b   Koehler, Michael F T ^c   Lessene, Guillaume ^a,b   Lowes, Kym ^a,b   Parisot, John P ^a,b   Smith, Brian J ^a,b   Smith, Morey L ^d   Souers, Andrew J ^d   Street, Ian P ^a,b   Yang, Hong ^a,b   Baell, Jonathan B ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GENENTECH INC   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N [7 [4 (4' CHLOROBIPHENYL 2 YLMETHYL)PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 DIMETHYLAMINO 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 NITROBENZENESULFONAMIDE; N [7 [4 (4' CHLOROBIPHENYL 2 YLMETHYL)PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 DIMETHYLAMINO 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 TRIFLUOROMETHANESULFONYLBENZENESULFONAMIDE; N [7 [4 (4' CHLOROBIPHENYL 2 YLMETHYL)PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 MORPHOLIN 4 YL 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 NITROBENZENESULFONAMIDE; N [7 [4 (4' CHLOROBIPHENYL 2 YLMETHYL)PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 MORPHOLIN 4 YL 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 TRIFLUOROMETHANESULFONYLBENZENESULFONAMIDE; N [7 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYLCYCLOHEX 1 ENYLMETHYL]PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 DIMETHYLAMINO 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 NITROBENZENESULFONAMIDE; N [7 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYLCYCLOHEX 1 ENYLMETHYL]PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 DIMETHYLAMINO 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 TRIFLUOROMETHANESULFONYLBENZENESULFONAMIDE; N [7 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYLCYCLOHEX 1 ENYLMETHYL]PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 MORPHOLIN 4 YL 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 NITROBENZENESULFONAMIDE; N [7 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYLCYCLOHEX 1 ENYLMETHYL]PIPERAZIN 1 YL]QUINAZOLIN 4 YL] 4 (3 MORPHOLIN 4 YL 1 PHENYLSULFANYLMETHYLPROPYLAMINO) 3 TRIFLUOROMETHANESULFONYLBENZENESULFONAMIDE; PROTEIN BCL 2; PROTEIN BCL XL; QUINAZOLINE SULFONAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BINDING, COMPETITIVE; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; HUMANS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 79952793550     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101596e     Document Type: Article

References (30)

1. Cory, S.; Adams, J. M. Killing cancer cells by flipping the Bcl-2/Bax switch Cancer Cell 2005, 8, 5-6 (Pubitemid 40991809)
2. Hinds, M. G.; Smits, C.; Fredericks-Short, R.; Risk, J. M.; Bailey, M.; Huang, D. C. S.; Day, C. L. Bim, Bad and Bmf: Intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets Cell Death Differ. 2007, 14, 128-136 (Pubitemid 44911900)
3. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer Cell 2000, 100, 57-70 (Pubitemid 30046295)
4. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 2007, 26, 1324-1337 (Pubitemid 46328466)
5. Labi, V.; Erlacher, M.; Kiessling, S.; Villunger, A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy Cell Death Differ. 2006, 13, 1325-1338 (Pubitemid 44057468)
6. Lessene, G.; Czabotar, P. E.; Colman, P. M. Bcl-2 family antagonists for cancer therapy Nat. Rev. Drug Discovery 2008, 7, 989-1000
7. Baell, J. B.; Huang, D. C. S. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs Biochem. Pharmacol. 2002, 64, 851-863 (Pubitemid 35232259)
8. van Delft, M. F.; Huang, D. C. S. How the Bcl-2 family of proteins interact to regulate apoptosis Cell Res. 2006, 16, 203-213 (Pubitemid 43247978)
9. The descriptor "BH3 mimetics" is somewhat misleading. Over a decade ago, Ripka and Rich (28) attempted to clarify terminology in peptidomimetic research and delineated between type II mimetics and type III mimetics. The former is a nonpeptide that is a functional mimetic and that binds to a peptide binding site but does not do so in a way that represents topographical mimicry of the native binding epitope. The latter is a topographical mimetic of the native binding epitope even though superficially it may be hard to envisage any resemblance between the two. The field of BH3 mimetics comprises both type II and type II peptidomimetics. We find this distinction useful. Despite this, the proposed classification of peptidomimetics of Ripka and Rich does not appear to have been widely taken up.
10. Oltersorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681 (Pubitemid 40825512)
11. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an Orally Bioavailable Small-molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins J. Med. Chem. 2008, 51, 6902-6915
12. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 2008, 68, 3421-3428
13. More recent progress in phase II trials can be found at http://clinicaltrials.gov and by searching on "Navitoclax" (or "ABT-263") and "phase II".
14. Huang, S.; Connolly, P. J.; Lin, R.; Emanuel, S.; Middleton, S. A. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621 Bioorg. Med. Chem. Lett. 2006, 16, 3639-3641 (Pubitemid 44164264)
15. Petros, A.; Dinges, J.; Augeri, D.; Baumeister, S.; Betebenner, D.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis J. Med. Chem. 2006, 49, 656-663 (Pubitemid 43157495)
16. Alternative coupling procedures involving attempted EDC/DMAP coupling between the hydroxyquinazoline and the sulfonamide, or from sulfonyltion of the 4-aminoquinazoline with the sulfonyl chloride, were all unsuccessful.
17. Wendt, M. D.; Shen, W.; Kunzer, A.; McClellan, W. J.; Bruncko, M.; Oost, T. K.; Ding, H.; Joseph, M. K.; Zhang, H.; Nimmer, P. M.; Ng, S. C.; Shoemaker, A. R.; Petros, A. M.; Oleksijew, A.; Marsh, K.; Bauch, J.; Oltersdorf, T.; Belli, B. A.; Martineau, D.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery and Structure Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo J. Med. Chem. 2006, 49, 1165-1181 (Pubitemid 43221663)
18. Lee, E. F.; Czabotar, P. E.; Smith, B. J.; Deshayes, K.; Zobel, K.; Colman, P. M.; Fairlie, W. D. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family Cell Death Differ. 2007, 14, 1711-1713 (Pubitemid 47278856)
19. Willis, S. N.; Chen, L.; Dewson, G.; Wei, A.; Naik, E.; Fletcher, J. I.; Adams, J. M.; Huang, D. C. S. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins Genes Dev. 2005, 19, 1294-1305 (Pubitemid 41003019)
20. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Martineau, D.; McClellan, W. J.; Mitten, M.; Ng, S. C.; Nimmer, P. M.; Oltersdorf, T.; Park, C. M.; Petros, A. M.; Shoemaker, A. R.; Song, X.; Wang, X.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL J. Med. Chem. 2007, 50, 641-662 (Pubitemid 46332978)
21. A final difference is that the structural modification and optimization of ABT-737 en route to ABT-263, which conferred improved bioavailability to the latter compound, did not have the same effect on the quinazoline sulfonamide system. Indeed, we undertook extensive pharmacokinetic analysis of all of the quinazolines reported herein and found that the oral bioavailability was low (<5%, data not shown). Both cell-based activity and pharmacokinetic behavior would therefore be the key parameters to improve in future medicina chemistry optimization for the quinazoline sulfonamides.
22. Baleizão, C.; Corma, A.; García, H.; Leyva, A. Oxime carbapalladacycle covalently anchored to high surface area inorganic supports or polymers as heterogeneous green catalysts for the Suzuki reaction in water J. Org. Chem. 2004, 69, 439-446 (Pubitemid 38101727)
23. Chen, L.; Willis, S. N.; Wei, A.; Smith, B. J.; Fletcher, J. I.; Hinds, M. G.; Colman, P. M.; Day, C. L.; Adams, J. M.; Huang, D. C. S. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function Mol. Cell 2005, 17, 393-403 (Pubitemid 40193310)
24. Czabotar, P. E.; Lee, E. F.; van Delft, M. F.; Day, C. L.; Smith, B. J.; Huang, D. C. S.; Fairlie, W. D.; Hinds, M. G.; Colman, P. M. Structural insights into the degradation of Mcl-1 induced by BH3 domains Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 6217-6222 (Pubitemid 47186075)
25. Lee, E. F.; Czabotar, P. E.; van Delft, M. F.; Michalak, E. M.; Boyle, M. J.; Willis, S. N.; Puthalakath, H.; Bouillet, P.; Colman, P. M.; Huang, D. C. S.; Fairlie, W. D. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation J. Cell Biol. 2008, 180, 341-355 (Pubitemid 351185920)
26. Lee, E. F.; Fedorova, A.; Zobel, K.; Boyle, M. J.; Yang, H.; Perugini, M. A.; Colman, P. M.; Huang, D. C. S.; Deshayes, K.; Fairlie, W. D. Novel Bcl-2 homology-3 domain-like sequences identified from screening randomized peptide libraries for inhibitors of the pro-survival Bcl-2 proteins J. Biol. Chem. 2009, 284, 31315-31326
27. Otwinowski, Z.; Minor, W. Processing of X-Ray Diffraction Data Collected in Oscillation Mode Methods Enzymol. 1997, 276, 307
28. Murshudov, G. G.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. 1997, D53, 240-255 (Pubitemid 27235885)
29. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics Acta Crystallogr. 2004, D60, 126-2132 (Pubitemid 41742764)
30. Ripka, A. S.; Rich, D. H. Peptidomimetic Design Curr. Opin. Chem. Biol. 1998, 2, 441-452 (Pubitemid 128645696)